Avelas Announces AVB-620 Presentation at 2016 San Antonio Breast Cancer Symposium
SAN DIEGO, Dec. 1, 2016 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced that research findings for the company's lead potential drug product, AVB-620, will be presented at the San Antonio Breast Cancer Symposium, taking place in San Antonio on December 6-10, 2016.
Presentation details are as follows:
Title: Intraoperative tumor detection using a ratiometric activatable fluorescent peptide: A first-in-human phase 1 study allows tumors to be visualized in the operating room.Authors: Unkart JT, Chen SL, González JE, Harootunian A, Wallace AMDate/Time: Thursday, December 8 from 7:30-9:00AM CST.Session: Poster Discussion 3: ImagingLocation: Henry B. Gonzalez Convention Center, San Antonio, TX 78205
About Avelas Biosciences
Avelas Biosciences is a San Diego-based biotechnology company focused on developing technologies that advance a new standard-of-care for cancer surgery and therapeutic intervention. The company's lead candidate, AVB-620 has completed enrollment of its Phase 1b trial for breast cancer assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. Avelas was founded by Avalon Ventures on technology from Nobel laureate Roger Y. Tsien, Ph.D. For additional information, please visit www.avelasbio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/avelas-announces-avb-620-presentation-at-2016-san-antonio-breast-cancer-symposium-300370851.html
SOURCE Avelas Bioscienes, Inc.